INSTITUTIONAL DIGITAL REPOSITORY

Targeted drug delivery to central nervous system (CNS) for the treatment of neurodegenerative disorders: trends and advances

Show simple item record

dc.contributor.author Goyal, K.
dc.contributor.author Koul, V.
dc.contributor.author Singh, Y.
dc.contributor.author Anand, A.
dc.date.accessioned 2021-09-20T06:28:31Z
dc.date.available 2021-09-20T06:28:31Z
dc.date.issued 2021-09-20
dc.identifier.uri http://localhost:8080/xmlui/handle/123456789/2717
dc.description.abstract The treatment of brain diseases has been a major challenge since a long time. Although there are several potent drugs, which are highly therapeutic yet their efficiency is marred due to the presence of the Blood Brain Barrier (BBB). The BBB, which is present at the capillary level regulates and monitors the entry of all small and large molecules entering into the brain. Although this barrier is of immense importance to the brain in terms of safety, it becomes a hindrance when it comes to therapy because the drug molecules are unable to reach the brain. Various biomaterial-based strategies are being developed to overcome the BBB and deliver the drug into the brain. These include polymeric nanoparticles, liposomes, solid-lipid nanoparticles (SLNPs), nanogels, implants, etc. This review provides an overview on CNS disorders, BBB, and various delivery strategies available for biologists engaged in translational neuroscience, to target CNS. en_US
dc.language.iso en_US en_US
dc.subject Blood-brain barrier (BBB) en_US
dc.subject CNS drug delivery en_US
dc.subject drug transport en_US
dc.subject targeting en_US
dc.title Targeted drug delivery to central nervous system (CNS) for the treatment of neurodegenerative disorders: trends and advances en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account